Log in to your Inderes Free account to see all free content on this page.
Xspray Pharma
26.65 SEK
-0.93 %
Less than 1K followers
XSPRAY
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-0.93 %
-0.16 %
+10.28 %
-12.86 %
+4.60 %
-15.83 %
-50.87 %
-68.32 %
-9.26 %
Xspray Pharma is a pharmaceutical company with several product candidates in clinical development that uses the patented HyNap technology to create improved versions of marketed protein kinase inhibitors. The drug candidate Dasynoc® is an amorphous form of dasatinib and is undergoing FDA review for market approval. Xspray Pharma's product portfolio also includes XS003-nilotinib, XS008-axitinib and XS025-cabozantinib.
Read moreMarket cap
1.26B SEK
Turnover
1.55M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
12.5.
2026
General meeting '26
5.8.
2026
Interim report Q2'26
5.11.
2026
Interim report Q3'26
All
Press releases
3rd party
ShowingAll content types
Interim Report First Quarter 2026
Xspray Pharma: Summer PDUFA dates put launch within reach - Edison
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio